Academic Journal

Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer

التفاصيل البيبلوغرافية
العنوان: Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer
المؤلفون: Carlo Cattrini, Davide Soldato, Alessandra Rubagotti, Linda Zinoli, Elisa Zanardi, Paola Barboro, Carlo Messina, Elena Castro, David Olmos, Francesco Boccardo
المصدر: Cancers; Volume 12; Issue 10; Pages: 2855
بيانات النشر: Multidisciplinary Digital Publishing Institute
سنة النشر: 2020
المجموعة: MDPI Open Access Publishing
مصطلحات موضوعية: prostatic neoplasms/mortality, prostatic neoplasms/epidemiology, SEER Program
الوصف: The real-world outcomes of patients with metastatic prostate cancer (mPCa) are largely unexplored. We investigated the trends in overall survival (OS) and cancer-specific survival (CSS) in patients with de novo mPCa according to distinct time periods. The U.S. Surveillance, Epidemiology, and End Results (SEER) Research Data (2000–2017) were analyzed using the SEER*Stat software. The Kaplan–Meier method and Cox regression were used. Patients with de novo mPCa were allocated to three cohorts based on the year of diagnosis: A (2000–2003), B (2004–2010), and C (2011–2014). The maximum follow-up was fixed to 5 years. Overall, 26,434 patients were included. Age, race, and metastatic stage (M1) significantly affected OS and CSS. After adjustment for age and race, patients in Cohort C showed a 9% reduced risk of death (hazard ratio (HR): 0.91 (95% confidence interval [CI] 0.87–0.95), p < 0.001) and an 8% reduced risk of cancer-specific death (HR: 0.92 (95% CI 0.88–0.96), p < 0.001) compared with those in Cohort A. After adjustment for age, race, and metastatic stage, patients in Cohort C showed an improvement in OS and CSS compared with Cohort B (HR: 0.94 (95% CI 0.91–0.97), p = 0.001; HR: 0.89 (95% CI 0.85–0.92), p < 0.001). Patients with M1c disease had a more pronounced improvement in OS and CSS compared with the other stages. No differences were found between Cohorts B and C. In conclusion, the real-world survival of de novo mPCa remains poor, with a median OS and CSS improvement of only 4 months in the latest years.
نوع الوثيقة: text
وصف الملف: application/pdf
اللغة: English
Relation: Cancer Therapy; https://dx.doi.org/10.3390/cancers12102855
DOI: 10.3390/cancers12102855
الاتاحة: https://doi.org/10.3390/cancers12102855
Rights: https://creativecommons.org/licenses/by/4.0/
رقم الانضمام: edsbas.155E8523
قاعدة البيانات: BASE